Andrew Huberman: Peptides, Sleep Tech, and the End of Obesity

Andrew Huberman (Stanford) on GLP-3 eradicating obesity, real-time cortisol sensing, and peptide roulette — with a16z’s Daisy Wolf

• Retatrutide (GLP-3, Lilly) enables up to 1/3 body weight loss with muscle-sparing; Huberman predicts >50% of Americans on GLPs in 5 years, mostly at sub-prescribed doses from compounding/gray market.
• Gray market peptide sources (99% purity, COA-backed) are meaningfully safer than black market ‘Chinese peptides’ — but 1% LPS contamination from repeated injections is an underappreciated risk.
• BPC-157 accelerates cartilage, nerve, and vascular regrowth — the vascular effect is the danger: it can vascularize existing tumors.
• Melanotan causes permanent skin color changes and priapism risk; Huberman explicitly warns against using it for cosmetic tanning.
• Real-time cortisol sensing is the missing wearable — a shifted diurnal cortisol curve (late trough) correlates with worse cancer outcomes and reduced longevity.
• Low-carb diets wreck sleep: cortisol stays elevated without starchy carbs; Huberman recommends carbs 2–4 hours before bed, especially post-resistance training.
• Sunosi (FDA-approved for EDS) outperformed Adderall in ADHD trials with a gentler arc — Huberman tried it, found it too stimulating, stuck with caffeine.
• WashU paper: Ritalin/Adderall improve focus ~equivalently to a full night’s sleep — they’re restoring baseline alertness, not enhancing cognition above it.
• Sleep tech thesis: cool the body (palms/soles), move eyes via mask for REM onset in <6 min, warm the room in the final hour to boost REM — all buildable now, nobody is building it.
• Octopus project: correlating camouflage patterns with behavior using real-time AI to decode cephalopod cognition — goal is cross-species communication, not training them to mimic humans.

Guests: Andrew Huberman (Stanford neurobiology professor, Huberman Lab podcast host), Daisy Wolf (a16z partner) · 2026-03-09 · Watch on YouTube